Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

Core Insights - The study demonstrates that Altamira's SemaPhore™ nanoparticles effectively deliver SOD2 mRNA to the aorta, resulting in significant reductions in aorta dilation, delayed rupture, and improved survival rates in an animal model of abdominal aortic aneurysm (AAA) [5][6]. Company Overview - Altamira Therapeutics is focused on developing RNA delivery technologies for targets beyond the liver, with a particular emphasis on peptide-based nanoparticle platforms like OligoPhore™ and SemaPhore™ [2][5]. - The company is advancing two flagship siRNA programs, AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis, both currently in preclinical development [2]. - Altamira holds a 49% stake in Altamira Medica AG, which markets Bentrio®, an OTC nasal spray for allergic rhinitis, and is exploring partnerships or divestments for its inner ear legacy assets [2][5]. Research Findings - The study, conducted by researchers from Washington University and the University of South Florida, indicates that systemic delivery of SOD2 mRNA via SemaPhore nanoparticles significantly mitigates AAA progression and enhances survival rates [5][6]. - The treatment approach targets oxidative stress, a key factor in AAA pathology, by boosting mitochondrial SOD2 expression, thereby reducing reactive oxygen species (ROS) levels [6]. Market Implications - The positive outcomes from the study suggest potential applications for SemaPhore nanoparticles in managing small AAAs and preventing ruptures, which could lead to new treatment options in the cardiovascular field [5][6].